Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > videos > molecularly-guided-treatment-intensification-metastatic-prostate-cancer

Molecularly Guided Treatment Intensification in Metastatic Prostate Cancer

2+ week, 2+ day ago   (839+ words) Andrew Hahn, MD, MD Anderson Cancer Center, Houston, Texas, presents a case of de novo metastatic prostate cancer to illustrate how comprehensive molecular profiling can inform upfront treatment selection. Hi, my name is Andy Hahn, I'm an assistant professor of…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > videos > subcutaneous-amivantamab-shows-promise-previously-treated-hpv-negative-head-and

Subcutaneous Amivantamab Shows Promise in Previously Treated HPV-Negative Head and Neck Cancer

1+ mon, 1+ week ago   (556+ words) Barbara Burtness, MD, Yale Cancer Center, New Haven, Connecticut, discusses results from cohort 1 of the phase 1b/2 OrigAMI-4 trial evaluating subcutaneous amivantamab monotherapy in patients with recurrent or metastatic HPV-unrelated head and neck squamous cell carcinoma following progression on platinum-based chemotherapy…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > videos > early-phase-immunotherapy-demonstrates-modest-activity-recurrent-or-metastatic-head

Early-Phase Immunotherapy Demonstrates Modest Activity in Recurrent or Metastatic Head and Neck Cancer

1+ mon, 2+ week ago   (306+ words) Harold Nathan Tan, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses findings from a retrospective analysis evaluating early-phase immunotherapy trials in patients with recurrent or metastatic head and neck squamous cell carcinoma. Good afternoon, everyone, I’m…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > videos > molecular-profiling-refines-prognosis-and-treatment-selection-low-grade-glioma

Molecular Profiling Refines Prognosis and Treatment Selection in Low-Grade Glioma

1+ mon, 2+ week ago   (218+ words) Brigitta Baumert, MD, PhD, Haaglanden Medical Center, The Hague, Netherlands, discusses long-term findings from the phase 3 EORTC 22033-26033 trial comparing upfront radiotherapy with dose-dense temozolomide in patients with clinically high-risk low-grade glioma. Hello, my name is Brigitta Baumert, and I am…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > videos > dual-ras-inhibition-demonstrates-promising-activity-kras-g12d-mutated-metastatic

Dual RAS Inhibition Demonstrates Promising Activity in KRAS G12D-Mutated Metastatic Pancreatic Cancer

1+ mon, 2+ week ago   (719+ words) HMP Global Learning Network Insights from the ESMO Gastrointestinal Cancers Congress Dual RAS Inhibition Demonstrates Promising Activity in KRAS G12D-Mutated Metastatic Pancreatic Cancer - Design/Population: This phase 1 study evaluated the combination of the KRAS G12D-selective RAS(ON) inhibitor zoldonrasib and…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > thederm > special-article > evolving-guidelines-management-high-risk-cscc

Evolving Guidelines for the Management of High-Risk CSCC

1+ mon, 3+ week ago   (784+ words) HMP Global Learning Network Evolving Guidelines for the Management of High-Risk CSCC CSCC is increasingly recognized as a heterogeneous disease, with a clinically distinct subset of tumors carrying a meaningful risk of recurrence, nodal metastasis, and disease-specific mortality.1,2 Historically, management…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > news > dostarlimab-meets-primary-end-point-registrational-azur-1-trial-dmmrmsi-h-rectal

Dostarlimab Meets Primary End Point in Registrational AZUR-1 Trial for dMMR/MSI-H Rectal Cancer

1+ mon, 4+ week ago   (383+ words) HMP Global Learning Network Dostarlimab Meets Primary End Point in Registrational AZUR-1 Trial for dMMR/MSI-H Rectal Cancer - Design/Population: The registrational phase 2 AZUR-1 trial evaluated dostarlimab monotherapy in patients with stage II/III mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H)…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > videos > real-world-neoadjuvant-immunotherapy-demonstrates-high-response-rates-dmmrmsi

Real-World Neoadjuvant Immunotherapy Demonstrates High Response Rates in dMMR/MSI Colorectal Cancer

1+ mon, 4+ week ago   (362+ words) The findings demonstrated complete response rates comparable to those reported in prospective studies while highlighting important differences in toxicity between treatment approaches. Ongoing translational analyses aim to identify biomarkers that can better guide patient selection and optimize the use of…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > news > longest-follow-enfortumab-vedotin-plus-pembrolizumab-confirms-durable-benefit

Longest Follow-Up of Enfortumab Vedotin Plus Pembrolizumab Confirms Durable Benefit in Advanced Urothelial Cancer

2+ mon, 6+ day ago   (446+ words) HMP Global Learning Network Longest Follow-Up of Enfortumab Vedotin Plus Pembrolizumab Confirms Durable Benefit in Advanced Urothelial Cancer - Design/Population: EV-103/KEYNOTE-869 dose escalation/cohort A evaluated first-line enfortumab vedotin plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic…...

HMP Global Learning Network
hmpgloballearningnetwork.com > site > onc > videos > ctdna-mrd-testing-lymphoma-what-it-and-how-it-works

ctDNA MRD Testing in Lymphoma: What It Is and How It Works

2+ mon, 6+ day ago   (520+ words) HMP Global Learning Network Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness. - h415.hmpgloballearningnetwork.com 2 AWSALB [x2]Registers which server-cluster is serving the visitor. This is used in context with load balancing,…...